CIP
OCUL icon

Convergence Investment Partners’s Ocular Therapeutix OCUL Stock Holding History

Convergence Investment Partners’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-19,100
Closed -$802K – 401
2015
Q1 		$802K Buy
+19,100
New +$628K 0.11% 281

Other funds holding OCUL

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
LCP
Lamond Capital Partners San Francisco, California $14.3M AUM 30.74% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Convergence Investment Partners's OCUL Position: Q2 2015 in Review

Convergence Investment Partners sold out of Ocular Therapeutix (OCUL) in Q2 2015, closing a stake of 19,100 shares — an estimated $802K sold.

Convergence Investment Partners first reported a position in OCUL in Q1 2015 and held it in 1 quarter. The position peaked at $802K in Q1 2015. 71 funds tracked by Wall St. Rank hold OCUL as of Q2 2015.

  • Convergence Investment Partners reported no remaining Ocular Therapeutix position as of Q2 2015 after selling out during the quarter.
  • Convergence Investment Partners sold 19,100 Ocular Therapeutix shares in Q2 2015, an estimated $802K.
  • Convergence Investment Partners first reported a position in Ocular Therapeutix in Q1 2015 and held it in 1 quarter.
  • Convergence Investment Partners's Ocular Therapeutix position peaked at $802K in Q1 2015.
  • 71 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2015.

Based on Convergence Investment Partners's 13F filing for Q2 2015, filed 5 Aug 2015.